<DOC>
	<DOC>NCT01922037</DOC>
	<brief_summary>This multicenter, prospective study will evaluate the correlation of participant's characteristics, including biomarkers, with predictive markers of clinical outcome in participants with moderate to severe asthma initiating treatment with omalizumab. During the 48 weeks, participants will be evaluated and treated per investigator discretion and will be followed from study entry until a maximum follow-up of 48 weeks, death, withdrawal of consent, loss to follow-up, or study closure.</brief_summary>
	<brief_title>A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Participants identified by the investigator as a candidate for treatment for asthma with omalizumab Confirmation of access to omalizumab through insurance or other source of funding Enrollment in any other concurrent clinical trial Participants for whom omalizumab treatment is contraindicated Participants who had a prior allergic reaction to omalizumab or its excipients Participants treated with omalizumab within the previous year Participants who received an experimental drug as part of another study within 3 months of enrollment</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>